- About Us
- Our BioBank Platform Technology
- Our Drug Programmes
- Contact us
Synairgen is a drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.
The business, focused primarily on COVID-19, severe asthma and COPD, discovers and develops novel therapies for respiratory disease. Its primary drug is SNG001, inhaled interferon beta, which is being investigated as a treatment for COVID-19.
Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. Its differentiating human biology BioBank platform of human tissue samples is used in these models to increase confidence in the likelihood of successful drug development.
The company’s SG016 Phase II trial of SNG001 in hospitalised COVID-19 patients produced positive topline results in July 2020, with more detailed results of primary endpoint analysis disclosed in September 2020. The results of this trial were published in The Lancet Respiratory Medicine Journal in November 2020, and can be accessed here.
Results from the Home Cohort of the SG016 trial, alongside an analysis of combined data from the Hospital and Home Cohorts, were announced by Synairgen on 30 April 2021. The results of the trial and combined cohort analysis can be accessed here.
Results from in vitro studies showing the antiviral activity of SNG001 against two SARS-CoV-2 variants, the "UK or Kent" and "South African" variants, were announced on 24 May 2021. Full details can be accessed here.
Interim analysis of SG015, Synairgen’s Phase II trial evaluating inhaled interferon beta (SNG001) in COPD patients, was conducted in September 2020. SNG001 was seen to be well tolerated in the older patient population and produced antiviral data which supports the COVID-19 program. This can be accessed here.
Part of Synairgen’s business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). In December 2017 the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a £5 million upfront payment and circa 17% of any future net partnering proceeds from all fibrotic indications.
Synairgen is quoted on AIM (LSE: SNG).